AUSTIN, Texas, May 8, 2018 /PRNewswire/ — TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions, announced today it has named Glenn Mattes as Chief Executive Officer of the Company. Mr. Mattes brings over…Read More
Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation Platform
The Series A financing will support further development of the Company’s pipeline of transformative dry powder drugs for pulmonary diseases and conditions. AUSTIN, TX, April 3, 2018/PR Newswire – TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of…Read More